AU2020380291A1 - Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine - Google Patents

Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine Download PDF

Info

Publication number
AU2020380291A1
AU2020380291A1 AU2020380291A AU2020380291A AU2020380291A1 AU 2020380291 A1 AU2020380291 A1 AU 2020380291A1 AU 2020380291 A AU2020380291 A AU 2020380291A AU 2020380291 A AU2020380291 A AU 2020380291A AU 2020380291 A1 AU2020380291 A1 AU 2020380291A1
Authority
AU
Australia
Prior art keywords
nac
brain
gsh
administering
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020380291A
Other languages
English (en)
Inventor
Douglas A. GREENE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuronasal Inc
Original Assignee
Neuronasal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronasal Inc filed Critical Neuronasal Inc
Publication of AU2020380291A1 publication Critical patent/AU2020380291A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AU2020380291A 2019-11-04 2020-11-04 Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine Pending AU2020380291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930473P 2019-11-04 2019-11-04
US62/930,473 2019-11-04
PCT/US2020/058905 WO2021092026A1 (en) 2019-11-04 2020-11-04 Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine

Publications (1)

Publication Number Publication Date
AU2020380291A1 true AU2020380291A1 (en) 2022-05-26

Family

ID=75688247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020380291A Pending AU2020380291A1 (en) 2019-11-04 2020-11-04 Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine

Country Status (7)

Country Link
US (2) US20210128509A1 (https=)
EP (1) EP4054410A4 (https=)
JP (2) JP2023500360A (https=)
CN (1) CN115515484A (https=)
AU (1) AU2020380291A1 (https=)
CA (1) CA3160283A1 (https=)
WO (1) WO2021092026A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof
WO2023192691A2 (en) * 2022-04-01 2023-10-05 Wake Forest University Health Sciences Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
US20250371713A1 (en) * 2024-05-28 2025-12-04 Debra Strick Rivera Mapping glutathione deficiency and/or dysfunction of mitochondria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
CA2871774C (en) * 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
ES2844199T3 (es) * 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Also Published As

Publication number Publication date
CN115515484A (zh) 2022-12-23
JP2023500360A (ja) 2023-01-05
EP4054410A4 (en) 2024-07-17
US20210128509A1 (en) 2021-05-06
WO2021092026A1 (en) 2021-05-14
CA3160283A1 (en) 2021-05-14
EP4054410A1 (en) 2022-09-14
JP2025107344A (ja) 2025-07-17
US20230321020A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US12414929B2 (en) Methods of treating brain disorders
AU2022283769B2 (en) Neuroactive steroids, compositions, and uses thereof
TWI326214B (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7855176B1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20190314297A1 (en) Combination therapy of cbd and copaxone
AU2020288908A1 (en) Liquid botulinum toxin composition for treating moderate to very severe glabellar lines and lateral canthal lines
US20240024267A1 (en) Methods of administering glutathione precursors
Herold Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder
WO2016057533A1 (en) Primary and secondary prevention of dementias and suicide with trace dose lithium
US20240000814A1 (en) Treating alcohol use disorder using psilocybin
Fonseka et al. Self-limiting cerebellar ataxia following organophosphate poisoning
Thakuri et al. Topical Atropine Induced Acute Psychosis-A case report
Akgun et al. Central nervous system stimulants and drugs that suppress appetite
WO2025257799A1 (en) Methods of treating dravet syndrome
HK40117702A (en) Liquid botulinum toxin composition for treating moderate to very severe glabellar lines and lateral canthal lines
EP4440578A1 (en) Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
Chen et al. Baclofen-induced reversible akinetic mutism
BLUMENREICH ACUTE TREATMENT OF VIOLENCE
PATRICIA of Violence
HK1152249B (en) Reduced volume formulation of glatiramer acetate and methods of administration